Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is at the forefront of developing innovative respiratory support technology as an alternative to invasive mechanical ventilation. The company's flagship product, INSPIRA ART100, is a breakthrough in Augmented Respiration Technology designed to maintain optimal oxygen levels in patients without the need for intubation and sedation. This technology is particularly significant in the treatment of respiratory failure and offers a less invasive option compared to traditional mechanical ventilation.
Inspira Technologies operates in various regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The company is involved in the research, development, manufacture, and marketing of proprietary respiratory care devices, aiming to transform the landscape of acute and neonatal care.
Recently, Inspira Technologies has announced several key developments:
- April 3, 2024: Commencement of a program to explore the use of the INSPIRA ART100 Device for an artificial womb for neonates requiring vital respiratory support.
- April 10, 2024: Collaborative development with Ennocure MedTech Ltd. on bio-electronic treatment to prevent bloodstream infections in ICU patients, showcasing a 100% reduction in bacterial growth within 24 hours in an in vitro study.
- April 16, 2024: Signing of a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100 device in organ transplant procedures.
- April 25, 2024: Receiving CSA Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- May 2, 2024: Initiation of the production of the INSPIRA ART100 medical device by a leading technology company.
- May 28, 2024: Notification of 510(k) class II clearance from the U.S. FDA for the INSPIRA ART100.
Inspira's products are designed not only to enhance patient outcomes but also to reduce the costs and complications associated with traditional respiratory support methods. The INSPIRA ART100 system has received FDA clearance, marking a pivotal moment in the company's history. Other products in the pipeline, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, are poised to further revolutionize respiratory care once approved.
Inspira Technologies (NASDAQ: IINN) announced a significant agreement with Sheba Medical Center for a clinical study of its HYLA blood sensor. This study will evaluate the sensor's non-invasive capabilities for continuous blood gas measurement in patients undergoing open heart surgery. Set to commence in Q1 2023, the results aim to enhance product development. The HYLA sensor is expected to improve real-time monitoring, which could lead to better patient outcomes and reduce healthcare costs.
Inspira Technologies OXY B.H.N. Ltd. (IINN) reported financial results for Q3 2022, with cash reserves of $16.2 million. The company is focused on developing the HYLA blood sensor for cardiopulmonary bypass surgery, aiming to enhance patient monitoring.
Research and development expenses surged to $6.2 million for the nine months ending September 30, 2022, while net loss reached $7.1 million. Inspira secured strategic agreements in Europe and the U.S. for the deployment of HYLA sensors, potentially valued at $26.1 million and $59 million, respectively.
Inspira Technologies (NASDAQ: IINN) announced a 5-year exclusive distribution agreement with Innovimed for the HYLA™ Blood Sensor, designed for continuous real-time blood parameter monitoring. The agreement requires Innovimed to purchase at least 1,364 sensors and 128,511 disposable units for hospitals in Poland, Czech Republic, and Slovakia. The collaboration aims to enhance market penetration in Europe while preparing for a clinical study of the HYLA™ Blood Sensor.
Inspira Technologies (NASDAQ: IINN) announced that the Israeli Patent Office has granted a patent for a key component of its INSPIRA ART system. This component, designed to secure a neck cannula, aims to enhance patient mobility and safety during treatment, potentially reducing reliance on invasive mechanical ventilation. The company plans to seek patent protections globally and is also considering early market entry for the component in the ECMO device market, which is valued at $531 million annually.
Inspira Technologies (Nasdaq: IINN) announced its participation in the iECOs Conference happening on November 10, 2022, in Tel Aviv, Israel. The company's CTO, Daniella Yeheskely-Hayon, Ph.D., will deliver a guest lecture during the Physiology and Technology session, showcasing Inspira's innovative respiratory support technology. This technology aims to enhance patient oxygen saturation levels while minimizing the need for invasive procedures. Additionally, the scientific team will be available at their booth to provide insights and answer questions about their ongoing product developments.
Inspira Technologies (NASDAQ:IINN, IINNW) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on October 22, 2022, at 7 p.m. ET. During the interview, President Joe Hayon will discuss the Company's InspiraART System and HYLA blood sensor, highlighting significant market opportunities and their product pipeline. The InspiraART technology aims to improve patient oxygen saturation while reducing reliance on invasive mechanical ventilation. The technology is yet to be tested in humans and is pending regulatory approval.
On September 7, 2022, Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced the completion of an animal study for its HYLA™ blood sensor at Lahav C.R.O. The sensor, which is non-invasive, offers real-time measurements of blood parameters, potentially improving patient monitoring and reducing risks compared to standard blood gas analyzers. The successful animal study follows earlier laboratory data and marks a significant step toward initiating human studies. This advancement is integral to Inspira's innovative respiratory support technology aimed at enhancing patient care.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that President Joe Hayon will present at the H.C. Wainwright 24th Annual Global Investor Conference on September 12, 2022, at 7:00 a.m. ET. One-on-one meetings with Hayon will take place on September 13-14, 2022. Inspira Technologies is known for its innovative Augmented Respiration Technology, aimed at improving patient oxygen saturation without invasive procedures. The technology is not yet approved for human use. For further details, visit their Investor Relations page.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) reported its Q2 2022 financial results, highlighting a net loss of $3.5 million, down from $8.2 million a year earlier. Cash reserves stood at $19.2 million as of June 30, 2022. The company's R&D expenses rose to $2.7 million, driven by increased projects and share-based compensation. Inspira introduced the HYLA™ non-invasive blood sensor and revealed the ALICE™ Device for cardiopulmonary bypass, targeting respective markets of $2.5 billion and significant deployment agreements in Israel and the U.S.
Inspira Technologies has introduced the Liby™ System, a next-generation extracorporeal membrane oxygenation (ECMO) device aimed at the $531 million global ECMO market. The company plans to submit for FDA approval in the first half of 2023, anticipating a Class II 510(k) designation that may not require human trials. The Liby™ system features innovative capabilities such as continuous patient monitoring integration with HYLA™ technology, reducing medical care costs through a consumable sales model.
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What is the market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What does Inspira Technologies do?
What is the INSPIRA ART100?
What regions does Inspira Technologies operate in?
What recent programs has Inspira Technologies announced?
Who are some of Inspira Technologies' partners?
Has the INSPIRA ART100 received regulatory approval?
What makes the INSPIRA ART100 different from traditional mechanical ventilation?
What is the significance of the CSA Certification of Compliance?
What is the financial impact of mechanical ventilation in the U.S.?
Where can I find more information about Inspira Technologies?
